The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk ...
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment ...
Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon). Patients with ...
Matthew J. Frigault, MD, and Adam D. Cohen, MD, outline how updated NCCN guidelines position CAR T-cell therapy in early ...
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal ...
Pathology Foundation Models: How AI models trained on millions of pathology slides are decoding complex tumor phenotypes and ...
McFarland, DO, and Ramy Sedhom, MD, discussed co-located psycho-oncology and palliative care, warm handoffs, and proactive distress screening. In this episode of Oncology On the Go, Daniel C.
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic ...
Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients ...
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care. Ursula A. Matulonis, MD, surveyed the exploitable genetic ...
Certainly also drugs that interact with DNA damage and repair. PARP inhibitors have a very fixed now role in how we take care ...
Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results